PF-08046054/​SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

To study a new treatment approach for people with locally advanced or metastatic non-small cell lung cancer whose disease has continued to grow after prior therapy. This study is comparing an investigational targeted therapy given alone or in combination with an immunotherapy medication to a standard treatment approach to see how well each works and how safe they are. The goal of the study is to learn whether the investigational approach may help control the cancer more effectively or with a different side effect profile.

• Adults 18+ years of age
• Diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has a PD-L1 expression of at least 1% and has progressed after prior standard treatments, including platinum-based chemotherapy and immunotherapy.
• Certain genetic mutations (such as EGFR or ALK) may also be eligible if they have already received the appropriate targeted therapies.
• No uncontrolled brain metastases, a recent history of other cancers (with some exceptions)
• No prior treatment with docetaxel or similar investigational agents, or serious uncontrolled medical conditions.

• Being randomly assigned to receive either the investigational drug PF-08046054 (SGN-PDL1V) or the chemotherapy drug Docetaxel given by intravenous (IV) infusion in repeating treatment cycles.
• Attending regular clinic visits for safety monitoring, physical exams, blood tests, and imaging scans to evaluate how the cancer responds to treatment and to monitor for side effects.
• Attending follow-up visits after treatment ends.